Figure 4. Clinical utility of prognostic IRG panel and IRGs-based prognostic index. (A) Overall survival, disease-free survival, cancer-specific survival, and progression-free survival of patients between high- and low-risk groups based on prognostic IRGs. (B) ROC curve analysis of risk score compared with clinicopathological features (age, gender, pathologic grade, clinical stage, tumor stage, lymph node metastasis and distant metastasis). (C, D) Differential risk scores, survival status and expression pattern of 6 IRGs in HCC patients. (E, F) Univariate and multivariate Cox regression analysis showing the independent prognostic value of this risk score. (G) Relationships between genes in the prognostic IRG panel and clinicopathological characteristics of HCC patients. (H) Pearson correlation analysis between risk score and infiltration abundances of immune cells. (I) Spearman correlation analysis between risk score and tumor mutation burden (TMB). (J) Spearman correlation analysis between risk score and microsatellite instability (MSI). (K) Heatmap visualization of the expression of 4 DNA mismatch repair (MMR) genes related to risk score. *** p = <0.001.